会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明申请
    • TARGETED GENETIC MANIPULATION USING MU BACTERIOPHAGE CLEAVED DONOR COMPLEX
    • 使用MU BACTERIOPHAGE CLEAVED DONOR COMPLEX的目标遗传操作
    • WO2002022835A2
    • 2002-03-21
    • PCT/US2001/028611
    • 2001-09-14
    • PIONEER HI-BRED INTERNATIONAL, INC.SUZUKI, HidekiLYZNIK, Leszek, Alexander
    • SUZUKI, HidekiLYZNIK, Leszek, Alexander
    • C12N15/70
    • C12N15/8213A01K2217/05A01K2217/075C12N15/8202C12N15/8206C12N15/902
    • Compositions and methods for targeted genetic manipulation of an organism are provided. The compositions are novel integration vectors derived from the Mu bacteriophage comprising an active cleaved donor complex (CDC) and further comprising a targeting mechanism whereby integration of the Mu transposable cassette may be directed to a predetermined target site within a host organism's genome. These integration vectors comprise a Mu transposable cassette and one or more navigator elements that direct targeted insertion of the CDC. Methods of the invention utilize the integration vectors of the invention to insert the Mu transposable cassette into a target site of an organism's genome. The insertion occurs in the absence of the MuB accessory protein. The methods are useful for modulating activity of known genes and for targeting integration of nucleotide sequences of interest into a specific location of an organism's genome. Accordingly, the methods may also be used to create gene disruptions and knockouts.
    • 提供了一种用于有机体靶向遗传操作的组合物和方法。 所述组合物是衍生自包含活性切割供体复合物(CDC)的Mu噬菌体的新型整合载体,并且还包含靶向机制,由此可将Mu转座盒的整合导向宿主生物体基因组内的预定靶位点。 这些整合载体包含Mu转座盒和一个或多个引导CDC的目标插入的导航器元件。 本发明的方法利用本发明的整合载体将Mu转座盒插入生物体基因组的靶位点。 插入发生在没有MuB辅助蛋白的情况下。 该方法可用于调节已知基因的活性并靶向将感兴趣的核苷酸序列整合到生物体基因组的特定位置。 因此,该方法也可用于产生基因破坏和敲除。
    • 9. 发明申请
    • POLYMER - ACTIVE AGENT CONJUGATES
    • 聚合物 - 主动代理商
    • WO2012102861A1
    • 2012-08-02
    • PCT/US2012/020959
    • 2012-01-11
    • FLEX BIOMEDICALWATHIER, MichelSUZUKI, Hideki
    • WATHIER, MichelSUZUKI, Hideki
    • A61K47/48A61P19/02
    • A61K47/48176A61K47/58
    • A polymer includes at least one monomeric unit represented by Formula I, II, or III: where X is CH 2 or O; R 1 is H, COOR 2 , COCH 3 , CONHR 2 , OR 2 or SR 2 ; L is a bond or a linker group; AA is a group derived from an active agent; each R 2 is independently H, a cation, an alkyl, an alkenyl, an alkynyl, COCH 3 , CH 2 CH 2 OH, CH 2 CH 2 OR 3 , an amino acid, a small peptide, a large peptide, enzyme, protein, growth factor, cytokine, antibody, single chain antibody, antibody fragment, COCCH 3 =CH 2 , COCH=CH 2 , CH 2 CO 2 H, CH 2 CH 2 CO 2 H, CH 2 CH 2 SH, CH 2 CH 2 SR 3 or (CH 2 CH 2 O) n' R 4 ; n' is an integer from 1 to 2000; each R 3 is independently trityl, 4-methyltrityl or 2 pyridyl; each R 4 is independently H, an alkyl, an alkenyl, an alkynyl, COCCH 3 =CH 2 , COCH=CH 2 , CH 2 CHO, CH 2 CH 2 CHO, CO 2 H, CO 2 R 5 , CH 2 CO 2 H, CH 2 CH 2 CO 2 H, CH 2 NH 2 , CH 2 NHR 5 , CH 2 N(R 5 ) 2 , CH 2 CH 2 NH 2 , CH 2 CH 2 NHR, CH 2 CH 2 N(R 5 ) 2 , SH, CH 2 CO 2 R 5 , orCH 2 CH 2 CO 2 R 5 ; and each R 5 is independently maleimide, a cation, an amino acid, a small peptide, a large peptide, protein, enzyme, growth factor, cytokine, antibody, single chain antibody, phosphate, sulfate, choline, or an activated ester.
    • 聚合物包括由式I,II或III表示的至少一个单体单元:其中X是CH 2或O; R1是H,COOR2,COCH3,CONHR2,OR2或SR2; L是键或连接基; AA是一种衍生自活性剂的基团; 每个R 2独立地是H,阳离子,烷基,烯基,炔基,COCH 3,CH 2 CH 2 OH,CH 2 CH 2OR 3,氨基酸,小肽,大肽,酶,蛋白质,生长因子,细胞因子,抗体,单链抗体 ,抗体片段,COCCH3 = CH2,COCH = CH2,CH2CO2H,CH2CH2CO2H,CH2CH2SH,CH2CH2SR3或(CH2CH2O)n'R4; n'是从1到2000的整数; 每个R 3独立地是三苯甲基,4-甲基三苯甲基或2-吡啶基; 每个R 4独立地是H,烷基,烯基,炔基,COCCH 3 = CH 2,COCH = CH 2,CH 2 CHO,CH 2 CH 2 CHO,CO 2 H,CO 2 R 5,CH 2 CO 2 H,CH 2 CH 2 CO 2 H,CH 2 NH 2,CH 2 NHR 5,CH 2 N(R 5)2,CH 2 CH 2 NH 2,CH 2 CH 2 NHR,CH 2 CH 2 N (R5)2,SH,CH2CO2R5或CH2CH2CO2R5; 每个R 5独立地为马来酰亚胺,阳离子,氨基酸,小肽,大肽,蛋白质,酶,生长因子,细胞因子,抗体,单链抗体,磷酸盐,硫酸盐,胆碱或活化酯。